Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation.
Anil Verma,Chase E. Hawes,Yashavanth Shaan Lakshmanappa,Jamin W. Roh,Brian A. Schmidt,Joseph Dutra,William Louie,Hongwei Liu,Zhong-Min Ma,Jennifer Watanabe,Jodie Usachenko,Ramya Immareddy,Rebecca L. Sammak,Rachel E. Pollard,J. Rachel Reader,J. Rachel Reader,Katherine J. Olstad,Katherine J. Olstad,Lark L. Coffey,Pamela A. Kozlowski,Dennis J. Hartigan-O'Connor,Dennis J. Hartigan-O'Connor,Michel C. Nussenzweig,Koen K. A. Van Rompay,Koen K. A. Van Rompay,John H. Morrison,John H. Morrison,Smita S. Iyer,Smita S. Iyer +28 more
TLDR
In this article, anti-viral monoclonal antibody (mAb) treatments may provide immediate but short-term immunity from coronavirus disease 2019 (COVID-19) in high-risk populations, such as people with diabetes and the elderly; however, data on their efficacy in these populations are limited.About:
This article is published in Cell Reports.The article was published on 2021-11-02 and is currently open access. It has received 8 citations till now.read more
Citations
More filters
Journal ArticleDOI
Antibody-mediated neutralization of SARS-CoV-2
Henning Gruell,Kanika Vanshylla,Timm Weber,Christopher O. Barnes,Christoph Kreer,Florian Klein +5 more
TL;DR: A review of the development, function, and potential use of neutralizing antibodies to prevent and treat CoV-2-associated coronavirus disease 2019 (COVID-19) can be found in this paper .
Journal ArticleDOI
SARS-CoV-2 infects neurons and induces neuroinflammation in a non-human primate model of COVID-19
Danielle Beckman,Alyssa C. Bonillas,Giovanne B. Diniz,Sean Ott,Jamin W. Roh,Sonny R. Elizaldi,Brian A. Schmidt,Rebecca L. Sammak,Koen K. A. Van Rompay,Smita S. Iyer,John Morris +10 more
TL;DR: In this article , the authors investigated whether SARS-CoV-2 reaches the brain and how viral neurotropism can be modulated by aging in a non-human primate model of COVID-19.
Journal ArticleDOI
Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19
David Gregory,Augustin G. L. Vannier,A Duey,T. Roady,Richard Kuo Dzeng,M. Pavlovic,Michael H Chapin,S. Mukherjee,Hannah Wilmot,Nic Chronos,Richelle C. Charles,Edward T. Ryan,Regina C. LaRocque,Tyler E. Miller,Wilfredo F. Garcia-Beltran,Julia Thierauf,A. John Iafrate,Steven Mullenbrock,Mark D Stump,Randall K. Wetzel,Roberto D. Polakiewicz,Vivek Naranbhai,Mark C. Poznansky +22 more
TL;DR: Seroprevalence of antibodies to specific SARS-CoV-2 and other betacoronavirus antigens in a well-annotated, community sample of convalescent and never-infected individuals obtained in August 2020 is studied to inform development of diagnostics, vaccines, and therapeutic antibodies, and provide insight into viral pathogenic mechanisms.
Journal ArticleDOI
Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation
Koen K. A. Van Rompay,Katherine J. Olstad,Rebecca L. Sammak,Joseph Dutra,Jennifer Watanabe,Jodie Usachenko,Ramya Immareddy,Jamin W. Roh,Anil Verma,Yashavanth Shaan Lakshmanappa,Brian A. Schmidt,Clara Di Germanio,Nabeela Rizvi,Hongwei Liu,Zhong-Min Ma,Mars Stone,Graham Simmons,Larry J. Dumont,Anton M. Allen,S. J. Lockwood,Rachel E. Pollard,Rafael Ramiro de Assis,Joann L. Yee,Peter B. Nham,Amir Ardeshir,Jesse D. Deere,Aarti Jain,Philip L. Felgner,Lark L. Coffey,Smita S. Iyer,Dennis J. Hartigan-O'Connor,Michael P. Busch,J. Rachel Reader +32 more
TL;DR: Overall, therapeutic benefits of CCP were marginal and inferior to results obtained earlier with monoclonal antibodies in this animal model, and can help to further optimize nonhuman primate models to provide proof-of-concept of intervention strategies, and guide the future use of convalescent plasma against SARS-CoV-2 and potentially other newly emerging respiratory viruses.
Journal ArticleDOI
Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later
Emma C Milligan,Katherine J. Olstad,Caitlin A. Williams,Michael L. Mallory,Patricio Cano,Kaitlyn Cross,Jennifer E. Munt,Carolina Garrido,Lisa C. Lindesmith,Jennifer Watanabe,Jodie Usachenko,Lincoln Hopkins,Ramya Immareddy,Yashavanth Shaan Lakshmanappa,Sonny R. Elizaldi,Jamin W. Roh,Rebecca L. Sammak,Rachel E. Pollard,Joann L. Yee,S. Herbek,Trevor Scobey,Dieter Miehlke,Genevieve G. Fouda,Guido Ferrari,Hongmei Gao,Xiaoying Shen,Pamela A. Kozlowski,David C. Montefiori,Michael G. Hudgens,Darin K. Edwards,Andrea Carfi,Kizzmekia S. Corbett,Barney S. Graham,Christopher B Fox,Mark A. Tomai,Smita S. Iyer,Ralph S. Baric,Rachel Reader,Dirk P. Dittmer,Koen K. A. Van Rompay,Sallie R. Permar,Kristina De Paris +41 more
TL;DR: In this article , the durability of vaccine efficacy against emerging variants of SARS-CoV-2 has been investigated for infants 6 months and older, and the authors demonstrated that broadly neutralizing and spike-binding antibodies against variants of concern (VOCs), as well as T cell responses, persisted for 12 months.
References
More filters
Journal ArticleDOI
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
David S. Khoury,Deborah Cromer,Arnold Reynaldi,Timothy E. Schlub,Timothy E. Schlub,Adam K. Wheatley,Jennifer A Juno,Kanta Subbarao,Stephen J. Kent,Stephen J. Kent,Stephen J. Kent,James A. Triccas,Miles P. Davenport +12 more
TL;DR: It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic is provided.
Journal ArticleDOI
Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
Davide F. Robbiani,Davide F. Robbiani,Christian Gaebler,Frauke Muecksch,Julio C. C. Lorenzi,Zijun Wang,Alice Cho,Marianna Agudelo,Christopher O. Barnes,Anna Gazumyan,Shlomo Finkin,Thomas Hagglof,Thiago Y. Oliveira,Charlotte Viant,Arlene Hurley,Hans Heinrich Hoffmann,Katrina G. Millard,Rhonda G. Kost,Melissa Cipolla,Kristie Gordon,Filippo Bianchini,Spencer T. Chen,Victor A. Ramos,Roshni Patel,Juan Dizon,Irina Shimeliovich,Pilar Mendoza,Harald Hartweger,Lilian Nogueira,Maggi Pack,Jill Horowitz,Fabian Schmidt,Yiska Weisblum,Eleftherios Michailidis,Alison W. Ashbrook,Eric Waltari,John E. Pak,Kathryn E. Huey-Tubman,Nicholas Koranda,Pauline R. Hoffman,Anthony P. West,Charles M. Rice,Theodora Hatziioannou,Pamela J. Bjorkman,Paul D. Bieniasz,Paul D. Bieniasz,Marina Caskey,Michel C. Nussenzweig,Michel C. Nussenzweig +48 more
TL;DR: Most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity, and rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
Journal ArticleDOI
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Eric J. Haas,Eric J. Haas,Frederick J. Angulo,John M McLaughlin,Emilia Anis,Emilia Anis,Shepherd Roee Singer,Shepherd Roee Singer,Farid Khan,Nati Brooks,Meir Smaja,Gabriel Mircus,Kaijie Pan,Jo Southern,David L. Swerdlow,Luis Jodar,Yeheskel Levy,Sharon Alroy-Preis +17 more
TL;DR: In this article, the real-world effectiveness of two doses of BNT162b2 against a range of SARS-CoV-2 outcomes and to evaluate the nationwide public-health impact following the widespread introduction of the vaccine was estimated.
Journal ArticleDOI
Vaccine hesitancy: the next challenge in the fight against COVID-19.
Amiel A. Dror,Netanel Eisenbach,Shahar Taiber,Nicole G. Morozov,Matti Mizrachi,Asaf Zigron,Samer Srouji,Eyal Sela +7 more
TL;DR: It is indicated that healthcare staff involved in the care of COVID-19 positive patients, and individuals considering themselves at risk of disease, were more likely to self-report acquiescence to CO VID-19 vaccination if and when available, and parents, nurses, and medical workers not caring for SARS-CoV-2 positive patients expressed higher levels of vaccine hesitancy.
Journal ArticleDOI
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
Rui Shi,Chao Shan,Xiaomin Duan,Zhihai Chen,Peipei Liu,Jin-Wen Song,Tao Song,Tao Song,Xiaoshan Bi,Xiaoshan Bi,Chao Han,Lianao Wu,Lianao Wu,Ge Gao,Xue Hu,Ya-Nan Zhang,Zhou Tong,Weijin Huang,William J. Liu,Guizhen Wu,Bo Zhang,Lan Wang,Jianxun Qi,Hui Feng,Fu-Sheng Wang,Qihui Wang,George F. Gao,Zhiming Yuan,Jinghua Yan +28 more
TL;DR: Two monoclonal antibodies isolated from a patient with COVID-19 are shown to interfere with SARS-CoV-2–receptor binding, and one displays potent action against this virus in vitro and in a rhesus macaque model.